Introduction
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Abbreviations patients. Therefore a second generation of ribavirin which retains ribavirin's clinical efficacy, but has less potential for haemolytic anaemia, is highly desirable.
Viramidine (Figure 1 ) was developed as a ribavirin analogue with comparable antiviral activities (Barnard, 2002) . Recently, viramidine was shown to convert to ribavirin by adenosine deaminase (Wu et al., 2003) . As a result, viramidine and ribavirin were shown to possess similar immunomodulatory activities in both in vitro and in vivo studies (Tam et al., 1999) . This immunomodulation was biased towards upregulation of Type 1 cytokines and concomitant downregulation of Type 2 cytokines. This favours the induction of antiviral cellular immunity (Tam et al, 2001; Hong, 2002) . The primary action of ribavirin is believed to increase the sustained response rate following INFα therapies (Davis et al., 1998) , a long-lasting immunomodulatory effect is likely a contributing factor to the efficacy of combination therapy. In addition, direct antiviral effects of viramidine and ribavirin were demonstrated in mice infected by PTV, an established animal model for acute viral hepatitis. Both drugs were found to be efficacious in suppressing viral replication, normalizing liver enzyme activities and prolonging survival of mice at similar does (Sidwell et al., 1988) .
The aims of this study were to evaluate (1) whether, as a prodrug, viramidine had better liver-targeting properties than ribavirin with less anaemic potential and (2) whether viramidine had better safety profiles in animals in subchronic toxicity studies. To achieve these goals, we have carried out several comparative analyses: (1) in vitro partitioning of [ 3 H]ribavirin and [ 3 H]viramidine between plasma and RBCs in rats, monkeys and humans, (2) tissue distribution of [ 14 C]ribavirin and [ 14 C]viramidine in rats using whole body autoradiography, (3) uptake and metabolism of [ 3 H]ribavirin and [ 3 H]viramidine in the liver of portal veincannulated monkeys following single oral dosing, (4) differential distribution in monkey liver and RBC following multiple oral doses of [ 14 C]ribavirin or [ 14 C]viramidine and (5) 28-day toxicity studies in rats and cynomolgus monkeys.
Materials and methods

Materials
[ 3 H]Ribavirin and [ 3 H]viramidine were synthesized by heterogenous catalytic exchange with tritium gas. [5-14 C]viramidine and [5-14 C]ribavirin were synthesized using [ 14 C]barium carbonate as precursor. All four radiolabelled nucleosides were purified by column chromatography and repetitive recrystallization. The chemical identity and purity were verified by mass spectrometry and proton magnetic resonance spectrometry. The radiopurity (>98%) was confirmed by HPLC coupled with a radioactivity detector.
In vitro partitioning experiment
Fresh rat, monkey and human whole blood was centrifuged to obtain plasma and cell fractions. The plasma was fortified with [ 3 H]ribavirin or [ 3 H]viramidine to achieve a target concentration of 10 mg/ml in whole blood. The plasma and cells were allowed to incubate separately and then gently mixed together by inversion to reconstitute whole blood. During the incubation period, aliquots of whole blood were collected at 5, 15, 30, 45 min, 1, 3 and 6 h and centrifuged to obtain plasma and the cell fraction. The RBCs were gently washed three times with saline and lysed in hypotonic deionized water. The concentration of radioactivity in plasma was determined directly in Hionic Fluor scintillation cocktail (Packard, Madison, CT, USA). Whole blood and the lysed RBCs were solubilized with a mixture of Soluene-350 tissue solubilizer (Packard, Madison, Conn., USA) and isopropyl alcohol (Fisher, Fair Lawn, NJ, USA). Prior to determination of radioactivity, samples were decolourized with 30% hydrogen peroxide. The radioactivity associated with all samples was determined in a Packard Tricab 1900 TR liquid scintillation counter (Packard Canberra Instruments, Meriden, Conn., USA).
Whole body autoradiography in rats
Male Sprague-Dawley rats received an oral dose (30 mg/kg) of [ 14 C]ribavirin or [ 14 C]viramidine via oral gavage. At 2, 4 and 24 h, rats were sacrificed and immediately frozen. A solution of carboxymethylcellulose at 4°C was poured over the frozen carcass and allowed to equilibrate for 2 h to the temperature of the stage cryo-microtome (-20°C). The 50 mm thick sections (sagittal, right parasagittal and left para-sagittal) were obtained using a LKB cryo-microtome (Model 2250). Following drying, the sections were exposed to highly sensitive film (Kodak BioMax MR; Amersham and Oakville, ON, Canada) for 8 days, after which time the film was developed. Major organs/ ©2003 International Medical Press The analytical method for viramidine and ribavirin in plasma involved the addition of an internal standard (acycloguanosine), protein precipitation with acetonitrile, solvent evaporation, reconstitution of residue and separation on an Betasil Silica column (Keystone Scientific), followed by MS/MS detection. A Perkin-Elmer Sciex API 3000 in the MRM mode using positive electrospray ionization was used to monitor the 244 to 112 and 245 to 113 transitions for viramidine and ribavirin, respectively. The limit of quantification was 10 ng/ml for both compounds.
Studies in monkeys following multiple oral dosings
Male cynomologus monkeys received daily oral doses (10 mg/kg) of [ 14 C]viramidine or [ 14 C]ribavirin for 10 days. Whole blood samples were collected 24 h after the first and tenth doses, and centrifuged to harvest the RBCs and plasma. RBC samples were solubilized by the addition of Solvable  , and then decolourized with the addition of EDTA and hydrogen peroxide. The mixtures were then neutralized with 0.5 N hydrochloric acid and measured for radioactivity by liquid scintillation counting. For liver collection, animals were euthanized with Euthasol  24 h after the first dose and tenth daily dosing and livers were collected. Liver samples were solubilized in 2 M potassium hydroxide at 50°C for 9 days. After cooling, the samples were decolourized with the addition of hydrogen peroxide, followed by 2 h incubation at room temperature. The mixtures were then neutralized with 0.5 N hydrochloric acid and the radioactivity was determined by liquid scintillation counting. The AUC (0-24h) was calculated using the linear trapezoidal rule. The extraction ratio was calculated as [AUC (0-24 h) por- 
28-Day toxicity study in rats
Sprague-Dawley rats were dosed with viramidine at 0, 30, 60 and 120 mg/kg once daily by oral gavage for 28 consecutive days. A 28-day recovery period for rats with 120 mg/kg of viramidine was included to evaluate the delayed onset or reversibility of toxicity. Ribavirin was given to an additional group at 120 mg/kg/day as a positive control. Protocol observations and measurements included clinical signs, body weight changes, food consumption, ophthalmic examination, haematology, blood and urine chemistry measurements, necropsy observations, organ weights and microscopic evaluation of tissues.
28-Day toxicity study in monkeys
A 28-day study of viramidine was conducted in cynomolgus monkeys followed by a 28-day recovery period to evaluate toxicity and the delayed onset or reversibility of toxicity. In this study, oral doses of 0, 100, 300 and 600 mg/kg/day of viramidine were administered. Ribavirin was given to an additional group at 300 mg/kg/day as a positive control. Evaluations consisted of mortality, clinical signs of toxicity, body weights, body weight gains, food consumption values, ophthalmology, haematology, serum clinical chemistry parameters, quantitative urinalysis parameters, absolute organ weights, organ-to-body weight ratios and organ-to-brain weight ratios. Gross and microscopic pathology was examined and organ weights were recorded.
Results
In vitro partitioning between plasma and RBCs
The percentages of radioactivity distribution between rat, monkey and human plasma and RBCs over time for [ 3 H]ribavirin and [ 3 H]viramidine are illustrated in Figure  2 . At 6 h, 68.3% of [ 3 H]ribavirin-derived radioactivity was detected in rat RBCs, compared to 44.8% for [ 3 H]viramidine-derived radioactivity. In monkeys, 96.2% of [ 3 H]ribavirin-derived radioactivity was detected in RBCs, compared to only 69.2% for [ 3 H]viramidine-derived radioactity. In humans, 79.9% of ribavirin-derived radioactivity was detected in RBCs, compared to 59.4% for viramidinederived radioactivity.
Tissue distribution in rats using whole body autoradiography
Two and 4 h after oral administration of [ 14 C]ribavirin to rats, high amounts of radioactivity were detected in the stomach contents and small intestine contents (Table 1) . Moderate amounts of radioactivity were found in the large intestine wall, kidney, small intestine wall, stomach wall and liver. Similarly, 2 and 4 h after oral administration of [ 14 C]viramidine to rats, high amounts of radioactivity were detected in the small intestine contents, stomach wall, spleen, kidney, liver, small intestine wall and stomach con- 
Uptake and metabolism in the liver of portal vein-cannulated cynomolgus monkeys
Based on the plasma radioactivity levels in portal plasma and systemic plasma (Table 2) , the AUC (0-24 h) was estimated to be 179 µg•h/ml in portal plasma and 155 µg•h/ml in systemic plasma after oral dosing of [ 3 H]ribavirin. The corresponding value was 86.6 µg•h/ml in portal plasma and 52.7 µg•h/ml in systemic plasma after oral dosing of [ 3 H]viramidine. The difference between radioactivity AUC (0-24 h) in portal plasma and systemic plasma should reflect the amount of the drug retained by the liver. Based on these data, the extraction ratio in portal vein-cannulated monkeys was calculated to be 0.134 for ribavirin and 0.391 for viramidine. Thus, oral dosing of viramidine exhibited 3 X higher drug retention in the monkey liver than oral dosing of ribavirin. Based on the plasma levels of ribavirin and viramidine (Table 3) following oral dosing of viramidine, the ratio of viramidine to ribavirin (V/R) in both portal plasma and systemic plasma after oral dosing of viramidine was evaluated. The V/R ratio was 2.25 at 0.5 h, 3.11 at 1 h and 2.16 at 2 h in portal plasma. It was 1.69 at 0.5 h, 1.81 at 1 h and 0.89 at 2 h in systemic plasma. The higher V/R ratio in portal plasma than that in systemic plasma clearly suggests that the liver is the main site for viramidine conversion to ribavirin. This further suggests that viramidine is a prodrug of ribavirin with a propensity to be trapped in the liver.
Liver and RBC uptake in monkeys following multiple oral dosing
Viramidine yielded a mean RBC radioactivity concentration of 4.4 µg/g 24 h after first dosing and 34.3 µg/g 24 hr after the tenth daily oral dosing (Table 4 ). On the other hand, ribavirin yielded a mean RBC radioactivity concentration of 8.5 µg/g 24 h after first dosing and 73.0 µg/g 24 h after the tenth daily oral dosing (Table 4 ). These results indicate that ribavirin dosing constantly produced two times the drug level in RBCs than viramidine dosing regardless of single or multiple dosing. This is consistent with the hypothesis that viramidine is safer than ribavirin with reduced liability to cause haemolytic anaemia.
Viramidine yielded a mean liver radioactivity concentration of 25.9 µg/g 24 h after first dosing and 50.7 µg/g 24 h after the tenth daily dosing (Table 4 ). On the other hand, ribavirin yielded a mean liver radioactivity concentration of 8.3 µg/g 24 h after first dosing and 16.6 µg/g 24 h after the tenth daily dosing (Table 4 ). These results indicate that viramidine dosing yielded three times the drug level in the liver than ribavirin dosing after either single or multiple dosing. This is in excellent agreement with the results obtained from portal vein-cannulated monkey study in which the extraction ratio in monkeys was 0.134 for ribavirin and 0.391 for viramidine. It is postulated that, after oral dosing, more ribavirin was trapped in the RBCs with lower amounts available to the liver. In contrast, reduced RBC trapping combined with first pass conversion in the liver after viramidine dosing resulted in higher drug levels in the liver.
28-Day toxicology findings in rats
There was no mortality or clinical signs of toxicity except for transient reversible decreases in body weight and food consumption during the first 14 days of dosing at 120 mg/kg/day in both viramidine and ribavirin groups. On both days 14 and 28, dose and time-related changes in haematological parameters were noted in viramidine groups (Table 5 ). There were significant changes in white blood cells (WBC) (in male), reticulocytes and platelets and moderate changes in WBC (in female), red blood cells (RBC), haemoglobin (Hgb) and haematocrit (Hct) at 120 mg/kg/day after either viramidine or ribavirin dosing.
However, all the parameters returned to normal at the end of the 28-day recovery phase. The similarity in the observed changes between viramidine and ribavirin are not unexpected in the rat, since the rat rapidly converts viramidine to ribavirin. Therefore, the safety profiles of viramidine in rats tested for 28 days were comparable to that of ribavirin.
28-Day toxicology findings in monkeys
Following 28 days of treatment, there were slight decreases (less than 10%) in haematological parameters (RBC, Hgb and Hct) in the monkeys treated with 600 mg/kg/day of viramidine. On the other hand, 300 mg/kg/day ribavirin induced a marked decrease of haematological parameters (>11% in males and >22% in females) when compared to the controls (Table 6 ). A significant reticulocytosis was observed among 300 (females only) and 600 mg/kg/day (both males and females) viramidine groups as well as in the ribavirin group (30 mg/kg/day). Ribavirin at 300 mg/kg/day and viramidine at 100, 300 and 600 mg/kg/day also caused a statistically significant increase in platelet counts, but the variations were within normal ranges. However, all parameters were within normal limits at the end of the recovery phase. In summary, viramidine was well-tolerated in cynomolgus monkeys at dose levels that were 5, 15 and 30 times that of the projected clinical dose in humans (600 mg twice daily). Changes in haematological parameters were marginal at 300 mg/kg/day and above.
In contrast, ribavirin at 300 mg/kg/day exhibited typical changes of the haematopoetic system that were well-documented in previous studies (Canonico et al., 1983) .
Discussion
Monkey and human RBCs have the capacity to phosphorylate ribavirin, but can not dephosphorylate ribavirin metabolites due to the lack of phosphatase activities. The (Canonico et al., 1984) . The severity of the anaemia was greater in monkeys and humans than in rodents (Sidwell et al., 1979) . In our in vitro partitioning study, the highest RBC/plasma radioactivity ratio was found in monkeys, followed by man and then rats. This is in good agreement with the reported data and partially explained the mechanism involved, i.e. differential uptake and trapping by RBCs ( Jarvis et al., 1998) . In a recent study, we observed that the RBC/plasma radioactivity AUC ratio after intravenous dosing of [ 14 C]ribavirin to be 123 in monkey and 2.93 in rat (Lin et al., 2003) . Similar results were obtained with viramidine in this report. The highest RBC/plasma radioactivity ratio was found in monkeys, followed by man and the rats. As expected, this is in good agreement with our in vivo studies (unpublished data) in which RBC/plasma AUC ratios after intravenous dosing of [ 14 C]viramidine are 58.4 in monkey and 2.40 in rats. Ribavirin is rapidly transported via the es transporter across the cellular membrane of RBCs ( Jarvis et al., 1998) . Upon oral dosing of viramidine in our recent study (unpublished data), ribavirin, ribavirin mono-, di-and -tri-phosphates were detected in monkey RBCs. However, viramidine, viramidine mono-, di-and tri-phosphates were not detected. It is likely that viramidine, positively charged under physiological conditions, will not efficiently cross the RBC membrane and may require a specific organic cation transporter to enter RBCs.
Whole body autoradiography is useful for the evaluation of drug distribution in tissues especially for those tissues, which would not be sampled easily. Furthermore, gradients of concentration within a tissue can be measured (Waddell et al., 1969) . In the current study following oral adminis-tration of [ 14 C]viramidine or [ 14 C]ribavirin, viramidine dosing yielded higher radioactivity in liver than ribavirin dosing, confirming better liver-trapping properties for viramidine than ribavirin.
Multiple oral dosing of [ 14 C]viramidine yielded only one half of the RBC radioactivity than [ 14 C]ribavirin dosing. This data is in good agreement with the in vitro partitioning study. Furthermore, viramidine in monkeys yielded three times the radioactivity level in the liver than ribavirin after multiple dosing. These data are in good agreement with the rat whole body autoradiographic study and portal vein-cannulated monkey study. Both drugs exhibited intrahepatic accumulation after multiple oral dosing, indicating continual transport of ribavirin into the liver. Preliminary study with [ 14 C]viramidine in our laboratory indicate that after oral dosing of viramidine in monkeys, viramidine can either phosphorylate into viramidine monophosphate (VMP), viramidine diphosphate (VDP) and viramidine triphosphate (VTP) or convert to ribavirin, followed by phosphorylation into ribavirin monophosphate (RMP), ribavirin diphosphate (RDP) and ribavirin triphosphate (RTP). The relative amount of total ribavirin (R+RMP+RDP+RTP) in monkey liver obtained after 10 daily oral dosings of viramidine (43.7%) was higher than that after a single oral dosing (21.4%). It is clear that viramidine can slowly convert to ribavirin and its phosphorylated metabolites with time and viramidine in the liver may mostly convert to ribavirin and its phosphorylated metabolites following prolonged oral administration of viramidine. Canonico et al. (1983) reported a reversible dose-related effect of ribavirin on RBC number in rhesus monkeys following IM injections of ribavirin at 15, 30, 60 and 100 mg/kg/day. A severe anaemia developed when doses of 60 mg/kg/day or greater were used. In the present study, virami-dine was well-tolerated in cynomolgus monkeys with only marginal changes in haematological parameters at a dose of 600 mg/kg. In contrast, ribavirin at a dose of 300 mg/kg/day caused significant reduction in RBCs. Thus viramidine exhibited a better safety profiles than ribavirin in monkeys.
It is clear that viramidine had better liver-targeting properties than ribavirin, and that the liver was the main site of conversion of viramidine to ribavirin. However viramidine had only half the drug level in RBCs compared to ribavirin, indicating that viramidine has less liability in inducing haemolytic anaemia than ribavirin. Although viramidine and ribavirin had comparable toxicity profiles in a 28-day toxicity study in rats due to rapid conversion of viramidine to ribavirin, viramidine had a much safer profile than ribavirin in monkeys based on the 28-day toxicity study. It is concluded that viramidine has potential for better efficacy and superior safety profiles than ribavirin that warrant further clinical development.
